MARKET

AERI

AERI

Aerie Pharmaceut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.93
-0.54
-8.35%
Closed 16:00 05/24 EDT
OPEN
6.42
PREV CLOSE
6.47
HIGH
6.53
LOW
5.75
VOLUME
800.30K
TURNOVER
3.26M
52 WEEK HIGH
19.26
52 WEEK LOW
5.46
MARKET CAP
288.33M
P/E (TTM)
-4.0231
1D
5D
1M
3M
1Y
5Y
Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
Benzinga · 7h ago
Aerie Pharmaceuticals begins dosing in late-stage study of AR-15512 for dry eye disease
Aerie Pharmaceuticals (NASDAQ:AERI) said the first person was dosed in a phase 3 trial of AR-15512 ophthalmic solution to treat the signs and symptoms of dry eye disease. The company
Seekingalpha · 9h ago
Aerie Pharmaceuticals Announces First Participant Dosed In The Phase 3 Registrational COMET-2 Study Of AR-15512 For The Treatment Of Dry Eye Disease
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program DURHAM,
Benzinga · 16h ago
BRIEF-Aerie Pharma Doses First Participant In Phase 3 Study Of Dry Eye Disease Treatment
reuters.com · 16h ago
Aerie Pharmaceuticals Doses First Participant in Phase 3 Trial of Dry Eye Disease Drug
MT Newswires · 19h ago
HC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00. Shares of Aerie Pharmaceuticals are trading down 3.54% over the last 24 hours, at $6.03 per share.
Benzinga · 05/09 16:03
--HC Wainwright Lowers Aerie Pharmaceuticals Price Target to $20 From $25, Buy Rating Kept
MT Newswires · 05/09 11:30
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
More
No Data
Learn about the latest financial forecast of AERI. Analyze the recent business situations of Aerie Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.00%Strong Buy
50.00%Buy
10.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average AERI stock price target is 18.67 with a high estimate of 30.00 and a low estimate of 6.00.
High30.00
Average18.67
Low6.00
Current 5.93
EPS
Actual
Estimate
-0.300.110.530.95
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 236
Institutional Holdings: 65.37M
% Owned: 134.45%
Shares Outstanding: 48.62M
TypeInstitutionsShares
Increased
48
5.83M
New
28
2.37M
Decreased
37
4.00M
Sold Out
21
3.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chief Executive Officer/Director
Raj Kannan
Co-Founder
Casey Kopczynski
Chief Financial Officer
Peter Lang
General Counsel/Secretary
John Larocca
Other
Gary Sternberg
Director
Barbara Finck
Independent Director
Gerald Cagle
Independent Director
Richard Croarkin
Independent Director
Mechiel Du Toit
Independent Director
David Gryska
Independent Director
Peter Mcdonnell
Independent Director
Benjamin Mcgraw
Independent Director
Julie Mchugh
No Data
No Data
About AERI
Aerie Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. The Company’s commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is under preclinical and clinical trials. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma. Rocklatan is under preclinical and clinical trials to be effective in reducing IOP.

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.